IRS1 and metabolic disease: In the context of metabolic disorders, studies suggest that melatonin restores the activity of the PI3K/AKT/mechanistic target of rapamycin (mTOR) pathway, reduces insulin receptor substrate-1 (IRS-1) phosphorylation, and increases insulin-like growth factor 1 (IGF-1) activity.